143 related articles for article (PubMed ID: 37179282)
21. Individualized preoperative planning using three-dimensional modeling for Bismuth and Corlette type III hilar cholangiocarcinoma.
Zeng N; Tao H; Fang C; Fan Y; Xiang N; Yang J; Zhu W; Liu J; Guan T; Fang C; Xiang F
World J Surg Oncol; 2016 Feb; 14(1):44. PubMed ID: 26911245
[TBL] [Abstract][Full Text] [Related]
22. Impact of
Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
[TBL] [Abstract][Full Text] [Related]
23. [Is 18F-FDG-PET suitable for therapy monitoring after palliative photodynamic therapy of non-resectable hilar cholangiocarcinoma?].
Müller D; Wiedmann M; Kluge R; Berr F; Mössner J; Sabri O; Caca K
Z Gastroenterol; 2005 May; 43(5):439-43. PubMed ID: 15871065
[TBL] [Abstract][Full Text] [Related]
24. Value of [
Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
[TBL] [Abstract][Full Text] [Related]
25. [Operation treatment method of Bismuth-Corlette Ⅲ, Ⅳ hilar cholangiocarcinoma].
Lu Z; Wang DD
Zhonghua Wai Ke Za Zhi; 2016 Jul; 54(7):488-91. PubMed ID: 27373472
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study.
Hwang JP; Moon JH; Kim HK; Lee MH; Lim CH; Park SB; Yoon JK; Park JM
Medicine (Baltimore); 2021 May; 100(21):e26015. PubMed ID: 34032720
[TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography and computed tomography with [
Pang Y; Zhao L; Shang Q; Meng T; Zhao L; Feng L; Wang S; Guo P; Wu X; Lin Q; Wu H; Huang W; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1322-1337. PubMed ID: 34651226
[TBL] [Abstract][Full Text] [Related]
28. Comparison of [
Chen H; Pang Y; Li J; Kang F; Xu W; Meng T; Shang Q; Zhao J; Guan Y; Wu H; Xie F; Wang J; Sun L
Eur Radiol; 2023 Feb; 33(2):1329-1341. PubMed ID: 35976396
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
[TBL] [Abstract][Full Text] [Related]
30. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
31. [Application of 3D visualization and 3D printing in individualized precision surgery for Bismuth-Corlette type Ⅲ and Ⅳ hilar cholangiocarcinoma].
Zeng N; Yang J; Xiang N; Wen S; Zeng S; Qi S; Zhu W; Hu H; Fang C
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Aug; 40(8):1172-1177. PubMed ID: 32895188
[TBL] [Abstract][Full Text] [Related]
32. Higher accuracy of [
Zhou X; Wang S; Xu X; Meng X; Zhang H; Zhang A; Song Y; Zhu H; Yang Z; Li N
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2983-2993. PubMed ID: 35543731
[TBL] [Abstract][Full Text] [Related]
33. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using
Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
[TBL] [Abstract][Full Text] [Related]
34. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
Kim JY; Kim MH; Lee TY; Hwang CY; Kim JS; Yun SC; Lee SS; Seo DW; Lee SK
Am J Gastroenterol; 2008 May; 103(5):1145-51. PubMed ID: 18177454
[TBL] [Abstract][Full Text] [Related]
35. Benefits of
Wen G; Gu J; Zhou W; Wang L; Tian Y; Dong Y; Fu L; Wu H
Eur Radiol; 2020 Sep; 30(9):5089-5098. PubMed ID: 32346795
[TBL] [Abstract][Full Text] [Related]
36. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT.
Li J; Kuehl H; Grabellus F; Müller SP; Radunz S; Antoch G; Nadalin S; Broelsch CE; Gerken G; Paul A; Kaiser GM
J Surg Oncol; 2008 Nov; 98(6):438-43. PubMed ID: 18767120
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the diagnostic efficacy of
Zhang Z; Jia G; Pan G; Cao K; Yang Q; Meng H; Yang J; Zhang L; Wang T; Cheng C; Zuo C
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2877-2888. PubMed ID: 35243518
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Diagnostic Efficacy of [
Zhang S; Wang W; Xu T; Ding H; Li Y; Liu H; Huang Y; Liu L; Du T; Zhao Y; Chen Y; Qiu L
Front Oncol; 2022; 12():925100. PubMed ID: 35847877
[TBL] [Abstract][Full Text] [Related]
39. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
Heusch P; Nensa F; Schaarschmidt B; Sivanesapillai R; Beiderwellen K; Gomez B; Köhler J; Reis H; Ruhlmann V; Buchbender C
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):42-8. PubMed ID: 25112399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
